Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877675 | 1.00 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL2877680 | 1.00 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL2882510 | 0.92 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL2882010 | 0.92 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6014198 | 0.92 | OPRL1 (0.70) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6492306 | 0.89 | OPRL1 (0.77) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6492309 | 0.89 | OPRL1 (0.77) | OPRL1KCNH2OPRM1HTR7 | |
| SCHEMBL6491405 | 0.89 | OPRL1 (0.77) | OPRL1KCNH2OPRM1HTR7 | |
| Hydrochloric Acid SCHEMBL6489568 | 0.88 | OPRL1 (0.76) | OPRL1KCNH2OPRM1HTR7 | |
| Hydrochloric Acid SCHEMBL6489565 | 0.88 | OPRL1 (0.76) | OPRL1KCNH2OPRM1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885KCNH2 969/4885OPRM1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.